Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Non-Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non-Current Assets for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 0.0% change, with the full-year FY2025 number at $5.0 million, changed 0.0% from a year prior.
  • Other Non-Current Assets was $5.0 million for Q4 2025 at TScan Therapeutics, roughly flat from $5.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.0 million in Q2 2022 to a low of $166000.0 in Q4 2021.
  • A 5-year average of $4.0 million and a median of $5.0 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 72.1% in 2021, then soared 2934.34% in 2022.
  • TScan Therapeutics' Other Non-Current Assets stood at $166000.0 in 2021, then skyrocketed by 2934.34% to $5.0 million in 2022, then dropped by 0.12% to $5.0 million in 2023, then changed by 0.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Other Non-Current Assets are $5.0 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025).